Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Phase 2 Active not recruiting 25 enrolled Omeros Corporation

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.

Timeline

Start: 2024-02-19
Primary completion: 2026-12
Completion: 2027-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZALTENIBART	Monoclonal antibody	5 mg/kg	Intravenous

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Summary

Timeline

Drugs

Indications